The concept of combining HSP90 inhibition with BRAF inhibition appeared more than a decade ago and despite seemingly favorable results in early preclinical studies, this combination strategy has yet to be developed further within the thyroid cancer field. The gene discussed is BRAF; the disease is thyroid cancer.